Fig. 1 · Structure

Documents & Downloads

Busulfan

Cat. No. A10169 CAS 55-98-1
Busulfan is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Busulfan is a bifunctional DNA-reactive alkylating compound. In an isolated-DNA assay, busulphan formed interstrand cross-links, with formation continuing through 24 hours. Cross-linking was relatively inefficient compared with the other dimethanesulphonates tested and required millimolar exposure in this cell-free system. These assay conditions do not define cellular potency. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A2780 IC50 > 100 μM In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line [PMID: 11277538]
Colon 26 IC50 92.5 μM In vitro cytotoxicity causing 50% growth inhibition was determined against C26-10 (murine colon carcinoma) cell line [PMID: 11277538]
CWR22R IC50 24.3 μM Growth inhibition of human 22Rv1 cells after 5 days by SRB assay [PMID: 32484346]
DU-145 IC50 25.8 μM Growth inhibition of human DU145 cells after 5 days by SRB assay [PMID: 32484346]
H322 IC50 > 100 μM In vitro cytotoxicity causing 50% growth inhibition was determined against H322 (human non small cell lung cancer) cells [PMID: 11277538]
Lewis lung carcinoma cell line IC50 > 100 μM In vitro cytotoxicity causing 50% growth inhibition was determined against LL (murine non small cell lung cancer) cell line [PMID: 11277538]
PC-3 IC50 36.2 μM Growth inhibition of human PC3 cells after 5 days by SRB assay [PMID: 32484346]
UMSCC22B IC50 > 100 μM In vitro cytotoxicity causing 50% growth inhibition was determined against 22B (human head and neck squamous) cell line [PMID: 11277538]
WiDr IC50 > 100 μM In vitro cytotoxicity causing 50% growth inhibition was determined against WiDr (human colon carcinoma) cell line [PMID: 11277538]

9 records · Scroll to view more

Busulfan Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Busulfan from 3 published references. In vitro models include early-passage normal human WI38 lung diploid fibroblasts; normal human WI38 fibroblasts.

Busulfan In Vitro Studies

In normal human WI38 fibroblasts, a 24-hour busulfan exposure induced sustained growth arrest, increased senescence-associated β-galactosidase staining and reduced DNA synthesis. Pharmacological inhibition of Erk-pathway signalling or p38 attenuated these effects, whereas p53 and JNK inhibitors did not provide significant protection. NAC attenuated oxidative stress and senescence in a separate intervention experiment. These findings support a redox-sensitive senescence response in this model; they do not establish a universal mechanism across cell types or complete antioxidant rescue. [2]

Biochemical assay · Linearized, end-labelled pBR322 DNA in a cell-free cross-linking gel assay [1]

Busulphan formed interstrand cross-links, with a signal increasing through 24 h. It was less efficient at 6 h than the three other dimethanesulphonates tested.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Interstrand cross-link formation and time courseQualitative gel and time-course result Cross-links detected at 1 mM; increasing through 24 h. At 6 h: Hexa-DMS > MDMS > Octa-DMS > busulphan.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM
Exposure duration
16 h for Fig.1; time course through 24 h in Fig.2
Method
Incubation at 37°C in 25 mM triethanolamine, 1 mM EDTA, pH 7.2; denaturation and agarose-gel microdensitometry. Native and denatured untreated DNA controls.
Vehicle
DMSO stock (250 mM), diluted in alkylation buffer; final solvent percentage not stated.
Co-treatment
None; other dimethanesulphonates were separate comparators.
Reported limits
Replicate count and uncertainty for Figs.1–2 are not stated in the paper. Final DMSO percentage and a separately identified solvent-matched control are not specified.
Methods and source locations

Compound reported in the paper: Busulfan; Compound label in the paper: Busulphan

Compound-level research evidence; tested material is not an Adooq lot and does not validate branded formulations.

pp.743–745, Chemicals and Interstrand crosslinking gel assay; Figs.1–2; p.746 Discussion

Interstrand cross-link formation and time course: Double-stranded DNA remaining after denaturation quantified relative to single-stranded DNA by microdensitometry. — p.744 Figs.1–2; p.745 Results

Senescence and pathway perturbation in WI38 fibroblasts

Cell-based study · Early-passage (<25) normal human WI38 lung diploid fibroblasts [2]

Busulfan produced lasting growth arrest, increased SA-β-gal staining and reduced BrdU incorporation. PD98059 and SB203580 attenuated these effects; α-pifithrin and SP600125 had no significant protective effect under the tested conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Day-11 senescence-associated β-galactosidase staining and BrdU incorporationPercentage positive cells, mean ± SEM; n = 6 SA-β-gal: BU 75.4 ± 6.6% vs control 9.7 ± 4.9%; BrdU: BU 3.6 ± 1.5% vs control 45.1 ± 4.7%; text reports p<0.0001 for each.[2]
Effects of pathway inhibitors on busulfan-induced senescence and recoveryQualitative direction and reported significance PD98059 and SB203580 attenuated senescence and restored BrdU incorporation/proliferation; α-PFT and SP600125 had no significant effect (p>0.05).[2]

Literature-Reported Treatment Conditions

Treatment concentration
120 μM
Exposure duration
24 h busulfan exposure followed by drug-free culture to day 11; recovery readouts after inhibitor removal where specified.
Method
SA-β-gal and BrdU staining, cell counting and Western blotting; untreated controls and inhibitor-vehicle comparison.
Vehicle
Inhibitor vehicle is labelled V in Fig.1; composition and busulfan solvent are not specified in the retrieved manuscript.
Co-treatment
Separate inhibitor conditions: α-PFT 20 μM, PD98059 50 μM, SB203580 1 μM or SP600125 20 μM. Pretreatment 30 min; inhibitors continued after busulfan washout through day 11, replenished every 3 d.
Reported limits
Solvent identity/concentration not specified. Caption n denotes observations without explicit biological-versus-technical replicate definition.
Methods and source locations

Compound reported in the paper: Busulfan; Compound label in the paper: BU

Compound-level research evidence; tested material is not an Adooq lot and does not validate branded formulations.

Methods: Reagents, Cell culture, proliferation, SA-β-gal, BrdU, Western and statistics; Results first subsection; Fig.1A–H

Day-11 senescence-associated β-galactosidase staining and BrdU incorporation: SA-β-gal microscopy and BrdU incorporation; untreated comparator. — Results first subsection; Fig.1B–C and caption

Effects of pathway inhibitors on busulfan-induced senescence and recovery: Separate pharmacological inhibitor arms; Fig.1F–H mean ± SEM, n=4. No numerical bar heights extracted. — Fig.1F–H and caption; Results first subsection

Antioxidant intervention in busulfan-treated WI38 cells

Cell-based study · Normal human WI38 fibroblasts [2]

N-acetyl-cysteine attenuated busulfan-associated oxidative stress and Erk/p38 phosphorylation and partially protected against senescence. This is a combination/intervention result; it does not establish complete restoration to untreated cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NAC effects on GSH, ROS, senescence and recoveryQualitative intervention effect NAC inhibited busulfan-associated GSH loss, ROS increase and SA-β-gal positivity, and improved BrdU incorporation and proliferation; two-way ANOVA p<0.05 across quantified endpoints (caption); n ≥ 3, mean ± SEM.[2]

Literature-Reported Treatment Conditions

Treatment concentration
120 μM busulfan; 1 mM NAC in intervention arms
Exposure duration
NAC pretreatment 24 h; busulfan 24 h; NAC continued after busulfan removal through day 11.
Method
Four conditions: untreated, NAC alone, busulfan alone and busulfan plus NAC. GSH at 30 min; ROS day 11; Western blots day 3; SA-β-gal day 11. BrdU and proliferation 3 and 5 d after NAC removal at day 11.
Vehicle
Medium control; busulfan solvent not specified in retrieved manuscript.
Co-treatment
NAC intervention, with NAC-alone and busulfan-alone controls.
Reported limits
Exact values for plotted bars not tabulated in retrieved text; not estimated. Biological-versus-technical meaning of n not explicitly resolved.
Methods and source locations

Compound reported in the paper: Busulfan; Compound label in the paper: BU

Compound-level research evidence; tested material is not an Adooq lot and does not validate branded formulations.

Methods: Reagents, Cell culture, GSH/ROS detection, Western and statistics; NAC Results subsection; Fig.4A–G and caption

NAC effects on GSH, ROS, senescence and recovery: GSH-bimane fluorescence, DHR oxidation, Western blots, SA-β-gal staining, BrdU and cell counts. No exact values inferred from graphs. — Fig.4A–G and caption; NAC Results subsection

Busulfan In Vivo Studies

A repeated busulfan regimen in female C57BL/6 mice was associated with lower white blood cell counts at week 15 and lower marrow-cell recovery at week 62 versus untreated controls. Red cells and platelets showed no significant changes, and all animals survived through week 15. Late morbidity and mortality reduced the cohort. The reported week-62 WBC comparison (P<.06) is retained without assigning significance at P<.05. This experiment supports persistent hematopoietic injury under the tested regimen, with no vehicle-matched control. [3]

Long-term hematopoietic effects in directly treated mice

Animal study · Female C57BL/6 mice; untreated CON, busulfan BSF and separate irradiation TBI cohorts [3]

The busulfan regimen reduced circulating white cells at week 15 and marrow-cell recovery at week 62. No significant RBC or platelet changes and no deaths through week 15 were reported. The late WBC result was reported as 57% lower with P<.06 and is not treated here as meeting P<.05.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
White blood cell counts relative to untreated CONReported relative reduction Week 15: 32%↓, P<.01; week 62: 57%↓, P<.06.[3]
Total bone-marrow-cell recovery at week 62Reported relative reduction 29%↓, P<.05 versus CON.[3]
Other blood lineages and survivalReported negative findings and attrition No significant RBC or platelet change at weeks 15 or 62. All animals alive at week 15; five BSF mice dead or moribund between weeks 15 and 62.[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Every other day, three injections within one week; course repeated four weeks later.
Treatment course
Two courses; observations at weeks 15 and 62 from treatment initiation.
Vehicle
Acetone stock diluted 1:10 with water; no matched vehicle control described.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Busulfan-treated direct cohort
30 mg/kg per injection
Untreated, age-matched CON; separate TBI comparison group, not co-treatment.WBC decreased at week 15; total marrow-cell recovery decreased at week 62. RBC and platelets did not change significantly. No deaths through week 15; five busulfan-group mice dead/moribund between weeks 15 and 62.[3]
Busulfan-treated direct cohort
Model: Female C57BL/6 mice, 10 weeks old at treatment; initially n=10 per control, busulfan and irradiation group.
Reported limits: Late sampling affected by deaths/morbidity and week-49 donor removal; initial n=10 is not the late endpoint sample size. Fig.2 specifies n=7 CON and n=4 BSF for terminal marrow analyses.
Methods and source locations

Compound reported in the paper: Busulfan; Compound label in the paper: BSF

Compound-level research evidence; tested material is not an Adooq lot and does not validate branded formulations.

Methods Animals and BSF/TBI treatments; Results Effects of BSF and TBI on hematopoiesis; Fig.1A–E

White blood cell counts relative to untreated CON: Automated blood counts. Week-62 P<.06 retained as reported; not relabelled significant at P<.05. — Fig.1B and Results Effects of BSF and TBI on hematopoiesis

Total bone-marrow-cell recovery at week 62: Cell counts extrapolated to total marrow assuming bilateral tibias/femurs contain 25% of total BM cells; plotted means with standard errors. — Fig.1C and Results Effects of BSF and TBI on hematopoiesis

Other blood lineages and survival: Longitudinal observation and automated blood counts; no cause-specific mortality attribution. — Fig.1B; Results Effects of BSF and TBI on hematopoiesis

Busulfan-treated direct cohort · Methods Animals and BSF/TBI treatments; Results Effects of BSF and TBI on hematopoiesis; Fig.1A–E

Specifications

Manufacturer Adooq Bioscience
CAS Number 55-98-1
Formula C6H14O6S2
Molecular Weight 246.3
Synonyms Myleran; Busulfex; Busulphan
SMILES
CS(=O)(=O)OCCCCOS(=O)(=O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 43 mg/mL (174.58 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
2% DMSO+30% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Busulfan Research References

  1. [1] M Ponti, R L Souhami, B W Fox, et al. DNA interstrand crosslinking and sequence selectivity of dimethanesulphonates British Journal of Cancer (1991). PMID: 1645563 DOI: 10.1038/bjc.1991.166 Source material
  2. [2] Virginia Probin, Yong Wang, Daohong Zhou. Busulfan-induced senescence is dependent on ROS production upstream of the MAPK pathway Free Radical Biology and Medicine (2007). PMID: 17512465 DOI: 10.1016/j.freeradbiomed.2007.03.020 Source material
  3. [3] Kaylind Batey, Jisoo Kim, Lauren Brinster, et al. Residual effects of busulfan and irradiation on murine hematopoietic stem and progenitor cells Experimental Hematology (2022). PMID: 34763024 DOI: 10.1016/j.exphem.2021.11.001 Source material

Added to your cart

View Cart Checkout
Loading...